These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 34214460)
21. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Lodde M; Lacombe L; Fradet Y Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155 [TBL] [Abstract][Full Text] [Related]
22. Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. Molenaar JP; Baten A; Blokx WA; Hoogendam A Eur Urol; 2009 Nov; 56(5):874-7; quiz 876. PubMed ID: 19171417 [TBL] [Abstract][Full Text] [Related]
23. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer]. Rusakov IG; Alekseev BIa Urologiia; 2002; (5):23-6. PubMed ID: 12402771 [No Abstract] [Full Text] [Related]
26. A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy. Bryk DJ; Angermeier KW; Klein EA Urology; 2019 Jul; 129():e4-e5. PubMed ID: 30935936 [TBL] [Abstract][Full Text] [Related]
27. Unusual presentation of advanced prostate cancer masquerading as metastatic and obstructing rectosigmoid cancer. Chang MD; Davidson AJ; Sutherland T; De Fontgalland D; Johnson D; Wong LM ANZ J Surg; 2017 May; 87(5):417-419. PubMed ID: 25388794 [No Abstract] [Full Text] [Related]
28. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011 [TBL] [Abstract][Full Text] [Related]
29. Is the use of anti-androgen monotherapy appropriate in patients with advanced prostate cancer? Roach M; Reese D; Weinberg V; Small EJ; Carroll PR J Clin Oncol; 2000 Jan; 18(2):448-50. PubMed ID: 10637263 [No Abstract] [Full Text] [Related]
30. The role of anti-androgen monotherapy in the treatment of prostate cancer. Bishop M BJU Int; 2003 Oct; 92(6):653-4. PubMed ID: 14511060 [No Abstract] [Full Text] [Related]
31. Estimated potency of Casodex: a problematic design. Labrie F; Simard J; Singh SM; Candas B Urology; 1997 Aug; 50(2):309-13. PubMed ID: 9255312 [No Abstract] [Full Text] [Related]
32. A new non-steroidal anti-androgen. Denis L Prog Clin Biol Res; 1989; 303():95-103. PubMed ID: 2675023 [No Abstract] [Full Text] [Related]
34. Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader. Hijab A; Taha T; Charas T; Bar-Sela G; Stein P; Agbarya A Anticancer Drugs; 2022 Jan; 33(1):e747-e751. PubMed ID: 34387605 [TBL] [Abstract][Full Text] [Related]
35. The clinical rationale for immediate androgen deprivation without estrogen deprivation. Pitts WR Clin Prostate Cancer; 2003 Sep; 2(2):127-8. PubMed ID: 15040875 [No Abstract] [Full Text] [Related]
36. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge. Rapkiewicz A; Gorokhovsky R; Farcon E; Das K Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888 [TBL] [Abstract][Full Text] [Related]
37. New drug for prostate cancer. Eur J Cancer Care (Engl); 2001 Jun; 10(2):79-80. PubMed ID: 11829051 [No Abstract] [Full Text] [Related]
38. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature. Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812 [No Abstract] [Full Text] [Related]
39. Bicalutamide versus flutamide in combination therapy. Labrie F; Candas B Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411 [No Abstract] [Full Text] [Related]